Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHANGE: Cetuximab + Chemotherapy in SCCHN
NCT01177956Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Dec 2009
- Primary completion
- Jan 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of KL-140 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Merck KGaA. Primary endpoint: Best Overall Response. Started Dec 2009; status: completed.
02
Drugs
KL-140
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01177956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01177956.